KPV Peptide | Benefits, Safety & Buying Advice [2026]

Photo by Innerbody Research

The word “inflammation” crops up a lot in health discussions, and that’s for good reason. Left unchecked, inflammation becomes a chronic health problem that spells serious trouble for your tissues and organs, immune function, and overall health. But inflammation stems from numerous possible causes, not all of which are under your control.

There’s a peptide, however, that might be able to police your body’s inflammatory response when you can’t. It’s called KPV.

In this guide, we explain how the KPV peptide works, break down the research into its effects, and discuss its availability to healthcare consumers.

But if you’re already set on trying KPV yourself, we’d recommend looking into a telehealth provider called Protocole.

Our Top Pick

Pharmaceutical-grade KPV is scarce on the market, but Protocole offers it in multiple stacks alongside complementary therapies, and at competitive prices.

At Protocole, you’ll find KPV paired with other peptides with wound-healing and anti-inflammatory effects, such as BPC-157, TB-500, and GHK-Cu. That sort of variety is hard to come by in the world of therapeutic peptides, much less with one as obscure as KPV. Protocole is actively expanding its catalog, but your KPV options already include multiple injectable treatment stacks and a topical. Once your membership application is approved (in as little as 30 minutes), you also gain access to Protocole’s team of clinicians, who can curate a suite of treatments tailored to your needs.

Jump to

Jump to:

Why you should trust us

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.

Our series on therapeutic peptides has taken us through articles on hundreds of clinical studies and other scientific sources on the subject, spread over more than 1,000 cumulative hours. KPV alone involved several dozen such sources and upwards of 30 hours. Along the way, we leaned on our relationships with people who know peptides on the ground level — both prescribers and patients. Although KPV isn’t yet an FDA-approved drug with widespread human use, these practical perspectives have allowed us to deduce its relative position in the larger peptide landscape.

Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

What is KPV?

KPV is a therapeutic tripeptide consisting of the amino acids lysine, proline, and valine (whose scientific abbreviations — K, P, and V — make up its name). Specifically, KPV is a fragment of alpha-melanocyte-stimulating hormone (α-MSH), a larger peptide with anti-inflammatory, antimicrobial, and fever-reducing properties.1 Even more specifically, the fragment in question is the C-terminal region of α-MSH, which is particularly good at neutralizing pathogens.2

While many therapeutic peptides are taken exclusively by needle, KPV stands apart in that it can also be administered as an oral capsule or chewable tablet. Its ability to be delivered through multiple routes may stem from a possible affinity for a peptide transporter, hPepT1, that occurs in the gastrointestinal tract.3 Researchers have also administered KPV topically or transdermally through technologies such as ionophoresis, which uses small electrical currents to drive the medication through the skin.4 There are even battery-integrated patches that use this technology.5 That being said, subcutaneous injection is likely the most rapid form of KPV drug delivery for systemic benefits, as well as the form you have the best chances of getting for your own use.

Primary therapeutic uses of KPV

KPV’s principal therapeutic value lies in its anti-inflammatory action. As your body’s natural response to harm from injury or illness, inflammation is essential for initiating the healing process. But when inflammation is severe or chronic, it becomes excessive and damages the body it’s meant to protect.6 Unless you get it back under control, it can contribute to serious health complications down the line — cardiovascular diseases, chronic obstructive pulmonary disease, cancer, and Alzheimer’s, to name a few.7 KPV’s role as a treatment is to prevent those complications from arising or worsening.

In addition, with its origins in α-MSH, KPV has demonstrated therapeutic value related to immune function, namely antimicrobial and wound-healing potential.

Of note, the research on KPV’s effects has been done primarily in animal models and human cell cultures, not in human subjects directly. Therefore, the support for its therapeutic uses is limited, albeit largely optimistic. Below, we discuss some of the most promising findings to date.

As an anti-inflammatory

KPV’s anti-inflammatory mechanism of action isn’t fully understood, but it may have to do with a signaling pathway called NF-κB. In a 2012 study published in the International Journal of Physiology, Pathophysiology and Pharmacology, KPV was found to suppress NF-κB, which is known to induce the expression of inflammatory genes and regulate the survival, activation, and differentiation of inflammatory T cells.8 9 Having this suppressive property, KPV could be a potential treatment for serious inflammatory health conditions affecting the lungs or gastrointestinal tract, in which the NF-κB pathway plays a key role.8 10 Indeed, a 2017 study in a mouse model observed that KPV administration led to significant downregulation of TNF-α, a major cytokine encoded by the pro-inflammatory TNFA gene and which uses the NF-κB pathway.11 12

As an antimicrobial

In 2000, the Journal of Leukocyte Biology published an in vitro study describing the effect that KPV (and α-MSH more broadly) could have on common pathogens. The pathogens in question were the bacterium Staphylococcus aureus and the fungus Candida albicans, which together account for nearly 150,000 infections and tens of thousands of deaths in the United States every year.13 14 The researchers found that even very small concentrations of the peptide not only killed significant amounts of these pathogens but also reduced their viability. Importantly, they noted that many anti-inflammatory drugs decrease the body’s immune function, but KPV doesn’t, concluding that its two-in-one action could be especially useful in the “treatment of disorders in which infection and inflammation coexist.”15

For wound-healing

The melanocortin 1 receptor (MC1R) is a key protein for regulating skin and hair color, but it’s also expressed in cell types involved in cutaneous wound healing. Moreover, it has a high affinity for α-MSH, and researchers have theorized that this affinity, alongside MC1R’s other characteristics, is what allows KPV to promote faster wound healing.16 An earlier study, from 2006, demonstrated the extent to which the peptide could do so. In it, rabbits who’d had their corneas mechanically wounded were given topical applications of KPV four times per day and had their wounds measured. After four days’ treatment, the KPV-treated rabbits exhibited significantly smaller wounds compared to the control group, and cultures of their corneal epithelial cells were found to be stimulated after KPV exposure.17

Is KPV safe?

The scientific literature says little about KPV’s safety profile, but there are concerns that it carries significant potential risks. From researchers, the most direct proclamation on the subject is found in the previously referenced 2017 mouse study, which described KPV as a “naturally derived tripeptide without any notable side effects,”11 but a weightier opinion given by the U.S. Food & Drug Administration (FDA) casts doubt on the study’s claim:

“FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.”18

In other words, there have been no dedicated safety studies on KPV, so its status as a safe or unsafe therapy is up in the air. But notably, the FDA made this statement in a release about bulk drug substances (ingredients used to make medicines) that it considers to pose “potential significant safety risks,” so KPV’s lack of safety studies is a red flag in the FDA’s eyes.

Apart from its unclear safety profile in clinical research, we can conclude, based on our dealings with prescribers, that KPV administered subcutaneously can cause certain side effects that are common to most therapeutic peptide injectables: injection site reactions and mild, transient flu-like symptoms. We also know that certain populations — pregnant or breastfeeding women and people with a history of cancer — are contraindicated for peptide use.

Research-grade vs. pharmaceutical-grade KPV

Pharmaceutical-grade drugs meet high chemical purity standards and have been approved or indexed by the FDA as being fit for human consumption. Research-grade drugs do not meet such standards and so are intended for laboratory use only.

KPV is not an FDA-approved drug, so much of the commercially available KPV through non-prescription online vendors will undoubtedly be research-grade material that is not fit for human consumption. If consumed, its relatively high level of impurities will elevate the risk of immunogenicity (a state in which the body’s immune system interprets a substance as a danger and mounts a potentially life-threatening response against it).19

Safe, pharmaceutical-grade KPV can be found online through reputable telemed platforms, but those opportunities are scarce right now, and you may first have to meet specific conditions. We discuss the matter further under “Where to find KPV” at the end of this guide.

What’s it like to use KPV?

No standard treatment protocol has yet been established for KPV, as it isn’t FDA-approved and few to no human trials have been conducted with it. The relatively scant number of reputable clinics that prescribe it may each have their own protocol that can’t be neatly homogenized here in summary. Therefore, it’s important that you have a licensed medical provider to consult about the specifics of a protocol suited to your needs, as well as to answer any questions about your treatment.

We can, however, deduce what your protocol is likely to be based on our findings in the existing literature, our familiarity with peptides in general, and the knowledge we’ve gained through relationships with both prescribers and users:

Preparation

As an injectable, KPV ought to come as a dry powder that must be reconstituted into a solution before use. The reconstitution process involves incorporating a measure of bacteriostatic water with the powder and gently mixing them together until the powder is dissolved.

In other forms (oral, topical), KPV should be good to go right out of the packaging — no preparation needed.

Dosage

Translated from rodent studies, a human-equivalent dose of KPV would start at around 0.2mg.12 But your dose may differ. Based on individual factors such as age, weight, and specific treatment circumstances, your prescribing doctor will determine the ideal dose for you.

For topical administration, a “dose” would be however much that minimally covers the target area.

Administration

Injectable KPV is self-administered via small needles into an area of subcutaneous tissue (e.g., belly, thigh, upper arm), not a vein. The needle size and injection site, together, help reduce the pain and discomfort of administration.

Topical KPV is applied directly to the target area of skin.

Dose frequency

Your dose frequency, too, is a matter that your prescribing doctor will determine based on your health history and needs. Like many therapeutic peptides, it may require daily (or near-daily) administration, as in the previously referenced mouse and rabbit studies.12 17 Moreover, as a preventive or a drug for managing chronic health conditions, treatment ought to be ongoing and may involve periodic breaks in dosing (cycling), which is also common with many therapeutic peptides. But as a reactive treatment for acute inflammation, infection, or wounds, dosing should end once the condition has resolved.

Storage

Injectable KPV should be stored at a temperature of 4°C, or 39°F, per the U.K.’s National Institute for Biological Standards20 — in the refrigerator, that is. Oral or topical versions probably don’t need to be kept at such low temperatures but should at least be kept in a cool, dry environment.

We normally include information about a peptide’s timeline of benefits, but to do the same with KPV would require an unreasonable amount of unhelpful conjecture. We could say, for example, that KPV’s antimicrobial benefits take effect within two hours (as in the study from 2000),15 but in real-world use, the treatment itself would take place across a longer timeline whose exact length can vary from person to person, case to case.

Meanwhile, the user wouldn’t notice KPV’s benefits in the same way they would with a weight-loss or focus peptide, because its effects don’t manifest so visibly. At most, one might eventually acknowledge that they feel better compared to an earlier state, but that isn’t like seeing a lower weight on the bathroom scale or noticing increases in sustained cognitive effort. The only measurable data related to KPV’s benefits are inflammatory biomarkers, microbial counts, and wound sizes, but the average user probably doesn’t have the means or interest to record those.

Who is (and is not) a candidate for KPV?

In a world where KPV is a widely available prescription, the prime candidates for its use would be people with chronic inflammation, persistent bacterial or fungal infections, or stubborn wounds. Within these populations are people with risk factors that might make them better candidates than others, such as:

• Stress: Chronic stress not only promotes an inflammatory state but also can prolong bacterial infections and discourage wound closure.7 21 22
• Overweight or obesity: People with excess weight are also at risk for chronic inflammation, persistent infections, and slower wound healing. That’s because having a higher proportion of body fat correlates with the release of more pro-inflammatory cytokines, an attendant decrease in immune function, and potentially increased wound tension from underlying adipose tissue, among other things.7 23 22
• Age: Older people tend to have more inflammatory molecules, possibly stemming from elevated levels of reactive oxygen species, which in turn can prolong wound-healing time.24 They’re also likely to have weakened immune systems, which reduces the ability to fight off infections as well as to heal wounds.25

Other risk factors also contribute to the health conditions that KPV can help treat (e.g., poor nutrition, poor sleep, and smoking), but they’re more feasibly reversible with other interventions. That’s to say that a person would do better to fix their diet, take supplements to sleep better, and quit smoking than to take KPV to address the downstream effects of their lifestyle.

Additionally, like other therapeutic peptides, KPV is likely contraindicated for pregnant or breastfeeding women and people with a history of cancer.

Where to find KPV

Searching online, you’re likely to encounter more than a few vendors offering KPV, but it’s a lot less likely that they’re dealing in a genuine pharmaceutical-grade peptide. What they’re really selling, probably, is research-grade material and just passing it off as pharmaceutical-grade. Remember, research-grade peptides are not suitable for human consumption, so taking stuff you bought online could lead to life-threatening circumstances.

Currently, as KPV remains on the FDA’s Category 2 list of restricted drugs, your options for getting the real deal are limited. Generally, you need to qualify for an exemption from the Federal Food, Drug, and Cosmetic Act.26 To do that, you must meet at least two criteria:27

• You must have a prescription for KPV from a licensed clinician
• You must need KPV to treat your health condition, as no other drug can safely or effectively treat it

Your ability to access treatment with medical-grade KPV depends on the assessment of a prescribing doctor — ideally, one who has clinical experience with therapeutic peptides, since they are effectively experimental drugs. To that end, there are some reputable clinics in the United States that prescribe KPV and other restricted peptides.

One example of a reputable clinic is Protocole, a telehealth provider with a large and growing catalog of therapeutic peptides. There, KPV is currently available in three stacks alongside complementary peptides (e.g., with BPC-157, TB-500, and/or GHK-Cu, which share wound-healing and anti-inflammatory actions with KPV). We’ve yet to find another online provider with as broad a selection or as comprehensive a service scope.

Photo by Innerbody Research

In a relatively short time, however, KPV may become more widely available to U.S. health consumers, as it’s among the 14 peptides that will be reviewed for potential reclassification in 2026 and 2027. Should it be successfully reclassified, we’ll update this guide accordingly and continue pointing you to the best pathways to prescription access.

Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

1. Dall’Olmo, L., et al. (2023). Alpha-melanocyte stimulating hormone (α-MSH): Biology, clinical relevance and implication in melanoma. Journal of Translational Medicine, 21, 562.

2. Singh, M., & Mukhopadhyay, K. (2011). C-terminal amino acids of alpha-melanocyte-stimulating hormone are requisite for its antibacterial activity against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 55(5), 1920-1929.

3. Viennois, E., et al. (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory pept1-mediated tripeptide KPV in a murine model. Cellular and Molecular Gastroenterology and Hepatology, 2(3), 340-357.

4. Pawar, K., et al. (2017). Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. Journal of Pharmaceutical Sciences, 106(7), 1814-1820.

5. Zhou, Y., et al. (2023). An integrated Mg battery-powered iontophoresis patch for efficient and controllable transdermal drug delivery. Nature Communications, 14(1), 1-12.

6. Cleveland Clinic. (2024). Inflammation. Cleveland Clinic.

7. Pahwa, R., Goyal, A., & Jialal, I. (2023). Chronic inflammation. StatPearls [Internet].

8. Land, S. C. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: Mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology, 4(2), 59-73.

9. Liu, T., Zhang, L., Joo, D., & Sun, S. (2017). NF-κB signaling in inflammation. Signal Transduction and Targeted Therapy, 2(1), 1-9.

10. Lu, D., & Zhao, H. (2020). Targeting NF-κB pathway for treating ulcerative colitis: Comprehensive regulatory characteristics of Chinese medicines. Chinese Medicine, 15, 15.

11. Xiao, B., et al. (2017). Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy, 25(7), 1628-1640.

12. Hayden, M. S., & Ghosh, S. (2014). Regulation of NF-κB by TNF family cytokines. Seminars in Immunology, 26(3), 253-266.

13. U.S. Centers for Disease Control and Prevention. (2019). Vital signs: Epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections — United States. CDC.

14. U.S. Centers for Disease Control and Prevention. (2024). Data and Statistics on candidemia. CDC.

15. Cutuli, M., et al. (2000). Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology, 67(2), 233-239.

16. Böhm, M., & Luger, T. (2019). Are melanocortin peptides future therapeutics for cutaneous wound healing? Experimental Dermatology, 28(3), 219-224.

17. Bonfiglio, V., et al. (2006). Effects of the COOH-terminal tripeptide α-MSH11–13 on corneal epithelial wound healing: Role of nitric oxide. Experimental Eye Research, 83(6), 1366-1372.

18. U.S. Food & Drug Administration. (2025). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA.

19. De Groot, A. S., et al. (2023). Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discovery Today, 28(10), 103714.

20. National Institute for Biological Standards and Control. (n.d.). Peptide handling, dissolution & storage. NIBSC.

21. Rosa, R. L., Johansen, H. K., & Molin, S. (2022). Persistent bacterial infections, antibiotic treatment failure, and microbial adaptive evolution. Antibiotics, 11(3), 419.

22. Guo, S., & DiPietro, L. (2010). Factors affecting wound healing. Journal of Dental Research, 89(3), 219-229.

23. Pugliese, G., et al. (2022). Obesity and infectious diseases: Pathophysiology and epidemiology of a double pandemic condition. International Journal of Obesity, 46(3), 449-465.

24. Khalid, K. A., et al. (2022). Aging and wound healing of the skin: A review of clinical and pathophysiological hallmarks. Life, 12(12), 2142.

25. Weyand, C. M., & Goronzy, J. J. (2016). Aging of the immune system. Mechanisms and therapeutic targets. Annals of the American Thoracic Society, 13(Suppl 5), S422-S428.

26. U.S. Food & Drug Administration. (2024). Bulk drug substances nominated for use in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA.

27. U.S. Food & Drug Administration. (2016). Prescription requirement under Section 503A of the Federal Food, Drug, and Cosmetic Act; Draft guidance for industry; Availability. FDA.